Are Eucrisa and Elidel the Same Thing?
Eucrisa (crisaborole) ointment and Elidel (pimecrolimus) cream are indicated for topical treatment of mild to moderate atopic dermatitis (eczema) in patients 2 years of age and older.
Eucrisa and Elidel belong to different drug classes. Eucrisa is a phosphodiesterase 4 inhibitor and Elidel is a calcineurin inhibitor.
What Are Possible Side Effects of Eucrisa?
Common side effects of Eucrisa include:
- application site pain
What Are Possible Side Effects of Elidel?
Common side effects of Elidel include:
- painful menstrual periods,
- upset stomach,
- muscle pain,
- increased sensitivity to hot or cold temperatures,
- cold symptoms such as stuffy nose or sneezing,
- swollen hair follicles,
- warts or skin bumps on treated areas,
- burning or warm feeling of treated skin, or
- stinging, tingling, or soreness of treated skin (especially during the first few days of treatment).
Serious side effects of Elidel include:
What is Eucrisa?
Eucrisa (crisaborole) ointment, 2%, for topical use is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
What is Elidel?
Elidel (pimecrolimus) is an immunodepressant cream formulation for short-term-only treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Elidel cream is available in other countries as pimecrolimus cream.
How Should Eucrisa Be Taken?
Apply a thin layer dose of Eucrisa twice daily to affected areas.
How Should Elidel Be Taken?
Elidel (pimecrolimus) is available in strength of 1% in a cream base in 30, 60 and 100 gram tubes. Usual dosage is to apply a thin cream film twice daily to the affected area of skin. Do not get cream into the eyes.
Skin Problems and Treatments Resources
Pfizer. Eucrisa Product Information.
Ortho Dernatologics. Elidel Product Information.